By Günter Jagschies, Senior Director, Strategic Customer Relations, GE Healthcare’s Life Sciences
The future role of biopharmaceuticals in developing global economies is evolving rapidly. The rising number of patients and the growing presence of noncommunicable diseases is creating an increased need for both existing treatment options, such as monoclonal antibodies (mAbs) as well as advanced strategies using cell and gene therapies and/or antibody-like drugs with enhanced potency. As the biopharma industry explores strategies to tackle this growing issue, it is critical we consider several factors about cell culture bioprocessing today and the impact they will have on the future of patient treatment.